A number of firms have modified their ratings and price targets on shares of Medidata Solutions (NASDAQ: MDSO) recently:

  • 7/24/2017 – Medidata Solutions was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/24/2017 – Medidata Solutions had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $95.00 price target on the stock, up previously from $94.00.
  • 7/21/2017 – Medidata Solutions had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $90.00 price target on the stock, up previously from $75.00.
  • 7/21/2017 – Medidata Solutions was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Medidata Solutions is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers’ clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer), investigator benchmarking and budgeting (Medidata Grants Manager), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave). Medidata’s diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes some top global pharmaceutical companies. “
  • 7/20/2017 – Medidata Solutions had its price target raised by analysts at Morgan Stanley from $74.00 to $86.00. They now have an “overweight” rating on the stock.
  • 7/18/2017 – Medidata Solutions had its price target raised by analysts at J P Morgan Chase & Co to $87.00. They now have an “overweight” rating on the stock.
  • 7/10/2017 – Medidata Solutions had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $94.00 price target on the stock, up previously from $77.00.
  • 7/7/2017 – Medidata Solutions had its price target raised by analysts at Piper Jaffray Companies to $87.00. They now have an “overweight” rating on the stock.
  • 6/27/2017 – Medidata Solutions had its price target raised by analysts at SunTrust Banks, Inc. from $80.00 to $90.00. They now have a “buy” rating on the stock.
  • 6/21/2017 – Medidata Solutions was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/14/2017 – Medidata Solutions was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/14/2017 – Medidata Solutions was given a new $74.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.

Shares of Medidata Solutions, Inc. (NASDAQ MDSO) traded up 1.71% during trading on Monday, hitting $79.04. 297,234 shares of the company were exchanged. The stock has a market capitalization of $4.48 billion, a PE ratio of 127.69 and a beta of 1.79. The company has a 50 day moving average of $77.80 and a 200-day moving average of $65.11. Medidata Solutions, Inc. has a 1-year low of $46.10 and a 1-year high of $85.92.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The company had revenue of $137.41 million during the quarter, compared to the consensus estimate of $134.28 million. During the same period last year, the company earned $0.24 EPS. Medidata Solutions’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, analysts forecast that Medidata Solutions, Inc. will post $1.28 earnings per share for the current year.

In related news, Director Robert Taylor sold 5,639 shares of Medidata Solutions stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $73.46, for a total value of $414,240.94. Following the completion of the sale, the director now directly owns 54,372 shares in the company, valued at approximately $3,994,167.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michael L. Capone sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $69.46, for a total value of $347,300.00. Following the completion of the transaction, the chief operating officer now directly owns 171,754 shares in the company, valued at $11,930,032.84. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by company insiders.

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Receive News & Ratings for Medidata Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.